Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibition of Oncogenic Protein Production at RNA Level
- Molecular classification
- RNA targeting therapeutics, siRNA, shRNA, Antisense oligonucleotide, MicroRNA, CRISPR-based RNA targeting
01
Overview
Inhibition of oncogenic protein production at the RNA level encompasses therapeutic strategies aimed at preventing the synthesis of cancer-promoting proteins by targeting their precursor RNA molecules. This approach disrupts the flow of genetic information from DNA to protein, intervening after transcription but before or during translation, thereby reducing or eliminating the production of harmful proteins that drive tumor growth and survival. Key modalities include RNA interference (RNAi) using siRNAs or shRNAs, antisense oligonucleotides (ASOs), microRNAs (miRNAs), and CRISPR-based technologies. Efficient delivery using nanoparticle carriers is crucial for stability and targeted delivery. Notable targets include MYC and NOVA1.
- Other names
- RNA-targeted cancer therapyPost-transcriptional gene silencing in cancermRNA-targeted therapeuticsRNA interference for cancer treatmentAntisense oligonucleotide therapy in cancer
02
Mechanism of action
Post-transcriptional gene silencing via siRNA/shRNA/RNAi/ASO/miRNA/sgRNA, leading to mRNA degradation or translation inhibition.
03
Biological functions
Gene silencingmRNA degradationTranslation inhibitionRegulation of gene expressionTumor suppression
04
Disease associations
CancerTumor growthDrug resistance
05
Safety considerations
Off-target effectsImmune stimulationDelivery challengesNuclease degradationLimited tissue penetration
06
Interacting drugs
siRNA-based drugs
2 more in the full profile.
07
Biomarkers
Oncogene mRNA levelsmiRNA expression profilesResponse to RNA-targeted therapy
Beyond the preview
Go deeper on Inhibition of Oncogenic Protein Production at RNA Level.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhibition of Oncogenic Protein Production at RNA Level.